Drugs / GSK256066
last change Dec 2008 re-read 2 minutes ago

GSK256066

Small molecule

Developed for
seasonal allergic rhinitis · asthma · chronic obstructive pulmonary disease
Investigated by
GlaxoSmithKline

Trials 10 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00515268 Sep 2007 → Apr 2008 chronic obstructive pulmonary disease GlaxoSmithKline Completed No outcome recorded
Phase 29 trials
Phase 2 NCT00612118 Feb → May 2008 seasonal allergic rhinitis GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00612820 Jan → May 2008 seasonal allergic rhinitis GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00549744 Nov 2007 → Aug 2008 asthma GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00549679 Oct 2007 → Dec 2008 chronic obstructive pulmonary disease GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00464568 Mar → May 2007 seasonal allergic rhinitis GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00430157 Jan 2007 → ? seasonal allergic rhinitis GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00380354 Sep 2006 → Jun 2007 asthma GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00445510 Jun 2006 → ? asthma GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00377728 Mar → May 2006 seasonal allergic rhinitis GlaxoSmithKline Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 11 sources stand behind the page.

FieldValueCited text
Known as GSK256066 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00445510
9

NCT00612118

NCT00380354

NCT00464568

NCT00377728

NCT00430157

NCT00549744

NCT00515268

NCT00549679

NCT00612820

Action Inhibit “phosphodiesterase-4 (PDE4) inhibitor” NCT00377728
Modality Small molecule CHEMBL570015
Route Intranasal “repeat doses of intranasal GSK256066” NCT00377728